CNSP - CNS Pharma enrolls 100 patients in glioblastoma multiforme treatment trial
2023-04-10 11:12:26 ET
- CNS Pharmaceuticals ( NASDAQ: CNSP ) said it had enrolled over 100 patients in trial to test its lead product candidate, Berubicin, to treat glioblastoma.
- The company had opened 43 clinical trial sites of the 60 sites selected across the U.S., Italy, France, Spain, and Switzerland.
- This drug will be tested in adult patients with recurrent glioblastoma multiforme after failure of standard first-line therapy compared to the standard of care.
- The primary endpoint of the study is the overall survival .
For further details see:
CNS Pharma enrolls 100 patients in glioblastoma multiforme treatment trial